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Summary
Background:  Loop  diuretics  have  two  different  classes  with  different  duration  of  activity:  short-
acting such  as  furosemide  (duration  of  activity,  6  h)  and  long-acting  such  as  azosemide  (duration
of activity,  10—12  h).  We  conducted  a  multicenter,  randomized,  controlled  trial  in  order  to
compare the  therapeutic  effects  of  azosemide,  a  long-acting  loop  diuretic,  and  furosemide,
a short-acting  one,  on  neurohumoral  factors  and  cardiac  function  in  outpatients  with  chronic
heart failure  (CHF).
Methods:  We  enrolled  98  patients  with  CHF  who  were  receiving  furosemide  and  an  angiotensin-
converting enzyme  inhibitor,  and  they  were  randomly  divided  into  furosemide  (n  =  49)  and
azosemide  (n  =  49)  groups.  The  furosemide  group  continued  furosemide  at  the  same  dosage,
and the  azosemide  group  switched  from  furosemide  to  azosemide.  At  baseline  and  after  3
months, we  measured  body  weight,  and  levels  of  brain  natriuretic  peptide  (BNP),  atrial  natri-
uretic peptide  (ANP),  norepinephrine,  active  renin,  creatinine,  blood  urea  nitrogen,  sodium,
potassium,  and  hematocrit.  Chest  X-ray  and  echocardiography  were  also  performed.
lasma  levels  of  BNP  and  ANP  signiﬁcantly  decreased  after  3  monthsResults:  Body  weight  and  p
in the  azosemide  group  compared  to  the  furosemide  group.  There  were  no  signiﬁcant  differ-
ences in  changes  of  levels  of  creatinine,  blood  urea  nitrogen,  sodium,  potassium,  hematocrit,
norepinephrine,  and  active  renin  after  3  months  between  the  furosemide  and  azosemide  groups.
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Echocardiography  and  chest  X-ray  did  not  demonstrate  signiﬁcant  differences  between  the  two
groups.
Conclusions:  Long-acting  azosemide  is  suggested  to  be  useful  for  the  improvement  of  neurohu-
moral factors  compared  with  short-acting  furosemide  in  patients  with  CHF.
© 2012  Japanese  College  of  Cardiology.  Published  by  Elsevier  Ltd.  All  rights  reserved.
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EchocardiographyIntroduction
Heart  failure  is  a  major  and  growing  public  health  prob-
lem,  and  the  number  of  heart  failure  deaths  has  increased
steadily  despite  advances  in  treatment  [1].  Diuretics  have
been  shown  to  improve  cardiac  function,  symptoms,  and
exercise  tolerance  in  patients  with  chronic  heart  failure
(CHF)  [2—4]. Loop  diuretics  with  strong  diuretic  effects  are
essential  for  the  treatment  of  pulmonary  congestion  and
symptoms  in  heart  failure  patients  [1].  The  loop  diuretics
are  categorized  into  short-  and  long-acting  groups  based  on
their  duration  of  action.  Furosemide  with  rapid  action  is  a
potent  diuretic  representing  the  short-acting  group,  while
azosemide  with  a  mild  and  long-lasting  effect  is  representa-
tive  of  the  long-acting  group  [5].
Despite  their  hypotensive  effects,  short-acting  calcium
channel  blockers  were  reported  to  increase  mortality  in
patients  with  cardiovascular  disease,  while  long-acting  cal-
cium  channel  blockers  were  not  associated  with  increased
mortality  in  hypertensive  patients  [6,7]. This  hypothesis
can  also  be  applied  theoretically  to  diuretics  with  differ-
ent  durations  of  action  in  patients  with  CHF.  Azosemide,
a  long-acting  loop  diuretic,  was  associated  with  a  better
outcome  in  Dahl  rat  heart-failure  models  compared  with
short-acting  furosemide,  partly  through  attenuation  of  the
reﬂex  increase  in  cardiac  sympathetic  neuronal  activity
caused  by  the  development  of  heart  failure  [8].  Further-
more,  the  comparative  effects  of  long-acting  azosemide  and
short-acting  furosemide  on  neurohumoral  factors,  and  the
usefulness  of  azosemide  for  improving  quality  of  life  were
shown  in  a  clinical  study  [9,10]. However,  these  studies  were
only  performed  in  a  small  number  of  patients  in  a  single  hos-
pital,  and  thus  the  usefulness  of  long-acting  diuretics  has  not
yet  been  validated.  Therefore,  we  conducted  a  multicenter
randomized  controlled  trial,  and  compared  the  effects  of
azosemide  on  neurohumoral  factors  and  cardiac  function  to
those  of  furosemide  in  outpatients  with  CHF  of  New  York
Heart  Association  (NYHA)  class  I—III.
Methods
Patients
We  enrolled  98  consecutive  CHF  outpatients  with  NYHA  class
I—III  whose  brain  natriuretic  peptide  (BNP)  level  was  greater
than  20  pg/ml,  who  had  been  receiving  an  angiotensin-
converting  enzyme  (ACE)  inhibitor  and  furosemide  for  at
least  1  month  and  were  in  a  stable  condition.  They  were
not  administered  any  angiotensin  II  type  1  receptor  blocker
(ARB).  The  diagnosis  of  heart  failure  was  deﬁned  by  symp-
toms,  clinical  signs,  and  BNP  levels  more  than  100  pg/ml
before  medication  [11].
C
b
Study  design
his  randomized  multicenter  clinical  trial  was  conducted  at
6  hospitals  in  Japan  from  October,  2005  to  January,  2008.
he  patients  were  randomly  divided  into  furosemide  and
zosemide  groups  by  an  envelope  method.  The  furosemide
roup  was  assigned  to  continue  receiving  furosemide,  and
he  azosemide  group  was  assigned  to  switch  from  furosemide
o  azosemide.  Regarding  the  doses  of  both  drugs,  20  and
0  mg  furosemide  was  equivalent  to  approximately  30  and
0  mg  azosemide,  respectively,  based  on  the  results  of  a  clin-
cal  pharmacology  study  [5].  Examinations  were  conducted
 months  after  registration,  and  all  clinical  parameters  were
xamined  before  and  3  months  after  assignment.  Readers  of
hest  X-ray  and  echocardiography  were  blinded  to  the  inves-
igation  in  the  treatment  allocation,  although  the  grouping
as  open  to  physicians  and  patients.
Concomitant  ACE  inhibitors  already  being  used  at  enroll-
ent  were  continued  as  prescribed.  Other  drugs  were
lso  allowed  to  continue  without  making  further  changes
fter  registration.  Cases  requiring  any  changes  in  medica-
ion,  including  other  heart  failure  drugs,  were  deﬁned  as
ropouts.
The  study  design  complied  with  the  Declaration  of
elsinki  and  was  unanimously  approved  by  the  Ethics  Com-
ittee  of  Kagoshima  University.  Written  informed  consent
as  obtained  before  enrolment  from  all  of  the  patients  who
articipated  in  the  present  study.
hysical  examination  and  chest  X-ray
he  NYHA  functional  class,  body  weight,  systolic  blood
ressure  (SBP),  diastolic  blood  pressure  (DBP),  and  cardio-
horacic  ratio  (CTR)  on  chest  radiography  were  determined
efore  and  3  months  after  commencing  the  study.
aboratory  examinations
 fasting  blood  sample  was  taken  in  the  morning.  The  plasma
evels  of  BNP,  atrial  natriuretic  peptide  (ANP),  norepineph-
ine  (NE),  and  renin  activity,  the  serum  levels  of  creatinine,
lood  urea  nitrogen,  sodium,  potassium,  and  chloride,  and
ematocrit  were  measured  before  and  3  months  after  assign-
ent.ardiac  function  was  evaluated  by  echocardiography
efore  and  3  months  after  the  start  of  the  clinical  trial.
tandard  two-dimensional  and  Doppler  echocardiographic
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Figure  2  Changes  in  body  weight  (A)  and  cardiothoracic
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igure  1  Scheme  and  principle  of  measurement  of  Tei  index.
xaminations  were  performed  in  all  subjects  using  1-  to
-MHz  phased  array  transducers  and  commercially  available
canners  [12]. Left  ventricular  systolic  dimension  (LVDs)  and
iastolic  dimension  (LVDd),  and  left  atrial  dimension  (LAD)
ere  determined.  Left  ventricular  ejection  fraction  (LVEF)
as  obtained  by  modiﬁed  biplane  Simpson’s  method  from
pical  2-  and  4-chamber  views.  LV  mass  was  calculated  by
he  American  Society  of  Echocardiography-recommended
ormula  [13]: LV  mass  (g)  =  0.8  × {1.04[(LVDd  +  posterior
all  thickness  +  interventricular  septum
hickness)3 − (LVDd)3]}  +  0.6  g.  LV  mass  was  divided  by
ody  surface  area  to  obtain  LV  mass  index  (LVMI).
Doppler  time  intervals  were  measured  from  the  left  ven-
ricular  (LV)  inﬂow  and  outﬂow  velocities,  and  Tei  index  was
etermined  as  shown  in  Fig.  1.  Interval  ‘‘a’’  was  measured
rom  the  cessation  of  LV  inﬂow  to  the  onset  of  the  next
nﬂow.  Interval  ‘‘b’’,  ejection  time,  was  measured  from  the
nset  of  LV  outﬂow  velocity  to  its  cessation.  LV  isovolumic
elaxation  time  (IRT)  was  calculated  by  subtracting  interval
‘d’’,  between  the  R  wave  on  the  electrocardiogram  and  the
essation  of  LV  ejection  ﬂow,  from  interval  ‘‘c’’,  between
he  R  wave  and  the  onset  of  LV  inﬂow.  LV  isovolumic  contrac-
ion  time  (ICT)  was  obtained  by  subtracting  IRT  from  (a  −  b).
ll  measurements  were  performed  from  three  consecutive
eats,  and  average  values  were  determined.  LV  Tei  index,
eﬁned  as  the  sum  of  the  isovolumic  contraction  and  relax-
tion  times  divided  by  the  ejection  time,  was  calculated
s  (a  −  b)/b  [14—16]. In  addition,  right  ventricular  (RV)  Tei
ndex  was  also  calculated  from  Doppler  time  intervals,  which
ere  determined  from  RV  inﬂow  and  RV  outﬂow  velocities.
V  and  RV  Tei  indices  represent  a  composite  of  systolic  and
iastolic  function  of  the  LV  and  RV,  respectively.
tatistical  analysis
alues  are  expressed  as  mean  ±  SD,  except  for  ANP  and  BNP
hich  are  shown  as  median  (25th  and  75th  percentiles).
aired  t-test  and  2 test  were  used  for  intra-group  com-
arison  (prior  to  and  3  months  after  initiation  of  the
rial),  and  unpaired  t-test  was  performed  for  inter-group
omparison  (comparison  of  changes  in  parameters  after
dministration  between  furosemide  and  azosemide  groups).
on-parametric  Mann—Whitney  U  test  was  used  for  non-
ormally  distributed  variables,  such  as  ANP  and  BNP.  A
-value  less  than  0.05  was  considered  to  indicate  signiﬁcant
ifference.
s
b
t
matio  (CTR)  on  chest  X-ray  (B)  after  3  months.  White  bars  are
urosemide  group;  black  bars  are  azosemide  group.
esults
atient  characteristics
inety-eight  patients  were  enrolled  and  randomly  divided
nto  furosemide  and  azosemide  groups.  One  patient  in  the
zosemide  group  was  excluded  from  the  trial,  because  she
omplained  of  frequent  urination  and  refused  the  continu-
tion  of  study.  There  were  no  other  adverse  drug  effects
n  either  group.  As  shown  in  Table  1,  there  were  no  sig-
iﬁcant  differences  in  patient  background  characteristics
etween  the  furosemide  (n  =  49)  and  azosemide  groups
n  =  48).  The  dose  of  furosemide  3  months  after  enroll-
ent  was  26.3  ±  10.5  mg/day,  and  that  of  azosemide  was
9.9  ±  25.3  mg/day.
ymptoms  and  physical  examination  ﬁndings
e  assessed  the  symptoms  and  physical  ﬁndings  at  the  start-
ng  point  and  3  months  after  enrolment,  and  compared  the
hanges  between  the  furosemide  and  azosemide  groups.
here  were  no  signiﬁcant  differences  in  NYHA  class,  SBP,
nd  DBP  between  the  two  groups.  Fig.  2A  shows  the  changes
n  body  weight  after  3  months  (Table  2).
In  comparison  with  the  azosemide  group,  patients  who
eceived  furosemide  gained  weight  while  administration  of
zosemide  induced  a  reduction  of  body  weight,  resulting  in  a
igniﬁcant  difference  in  the  change  of  body  weight  between
he  two  groups  (p  <  0.05).  Chest  X-ray  showed  no  signiﬁcant
ifference  in  the  change  of  CTR  between  the  two  groups
Fig.  2B).
aboratory  measurements
ver  the  3  months  of  the  study,  there  were  no  signiﬁcant
ifferences  in  changes  of  creatinine,  blood  urea  nitrogen,
odium,  potassium,  and  chloride  levels,  and  hematocrit
etween  the  furosemide  and  azosemide  groups,  although
he  creatinine  levels  were  signiﬁcantly  increased  after  3
onths  in  both  groups  (Table  2).
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Table  1  Patient  characteristics.
Parameter  Furosemide  group  (n  =  49)  Azosemide  group  (n  =  48)  p-value
Age  (year)  75.7  ±  7.9  75.8  ±  9.6  0.957
Sex
Male 30  (61.2%)  21  (43.7%) 0.129
Female  19  (38.8%)  27  (56.3%)
Body weight  (kg)  53.7  ±  11.1  56.3  ±  12.1  0.267
Height (cm)  154.0  ±  9.6  154.5  ±  11.3  0.807
NYHA
Class I 14 14 0.882
Class  II 33 31
Class  III 2 3
CTR  (%) 54.6  ±  5.5 55.7  ±  6.6 0.405
LVEF (%)  58.0  ±  16.2  59.8  ±  13.7  0.554
LVDd (mm)  51.2  ±  7.9  48.2  ±  9.7  0.092
LVDs (mm)  35.2  ±  9.7  33.3  ±  8.0  0.314
LAD (mm)  42.7  ±  8.1  41.9  ±  7.1  0.621
LVMI (g/m2)  137.1  ±  35.5  130.1  ±  43.5  0.392
LV Tei  index  0.49  ±  0.20  0.46  ±  0.16  0.369
RV Tei  index  0.33  ±  0.13  0.32  ±  0.13  0.687
BNP (pg/ml)  90.2  (51.2,  160.0)  102.5  (58.7,  211.5)  0.218
ANP (pg/ml)  31.0  (21.0,  53.0)  48.0  (28.0,  61.0)  0.139
Etiology of  heart  failure
Valvular  disease  29  26
Ischemic  heart  disease 12  13  0.966
Dilated cardiomyopathy 6 7
Hypertensive  heart  disease 2  2
ACE inhibitors
Enalapril 29  25
Imidapril 20 21  0.236
Delapril 0 2
 blocker 9 9  0.832
Spironolactone 7 8 0.785
Statin 10 12 0.634
Digitalis 12 13 0.819
Nitrate 11 13 0.644
Values are mean ± SD except for ANP and BNP which are shown as median (25th and 75th percentiles); NYHA, New York Heart Association;
CTR, cardiothoracic ratio; LVEF, left ventricular ejection fraction; LVDd, left ventricular end-diastolic dimension; LVDs, left ventricular
end-systolic dimension; LAD, left atrial dimension; LVMI, left ventricular mass index; LV, left ventricular; RV, right ventricular; BNP, brain
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Neurohumoral  factors
With  regard  to  plasma  levels  of  BNP  and  ANP,  the  azosemide
group  showed  a  decline  in  these  two  factors  whereas  the
furosemide  group  showed  an  increase  in  both  parameters,
demonstrating  signiﬁcant  differences  in  the  changes  in  these
two  markers  between  the  two  groups  (p  <  0.05,  Fig.  3A  and
B).  In  contrast,  there  were  no  signiﬁcant  differences  in
changes  of  plasma  levels  of  norepinephrine  and  renin  activ-
ity  after  3  months  between  the  furosemide  and  azosemide
groups  (Table  2).
EchocardiographyLV  Tei  index  tended  to  increase  after  3  months  in  the
furosemide  group,  while  it  decreased  in  the  azosemide
group;  however,  there  was  no  signiﬁcant  difference  in  the
[
e
(
(onverting enzyme; NS, not signiﬁcant.
hanges  between  the  groups  (Fig.  4A).  Although  RV  Tei  index
igniﬁcantly  increased  after  3  months  in  the  furosemide
roup,  there  was  no  signiﬁcant  difference  in  changes  in  RV
ei  index  between  the  groups  (Fig.  4B).  There  were  no  sig-
iﬁcant  differences  in  changes  in  LVDd,  LVDs,  LVEF,  LAD,  and
VMI  after  3  months  between  the  furosemide  and  azosemide
roups.
iscussion
oop  diuretics  are  regarded  as  suitable  for  improving  pul-
onary  congestion  and  heart  failure  symptoms  by  reducing
reload,  as  described  in  the  guidelines  for  treatment  of  CHF
17].  Loop  diuretics  have  two  different  classes  with  differ-
nt  duration  of  activity:  short-acting  such  as  furosemide
duration  of  activity,  6  h)  and  long-acting  such  as  azosemide
duration  of  activity,  10—12  h)  [5].  In  the  present  study,
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Table  2  Changes  in  blood  pressure,  PRA,  NE,  BUN,  Cr,  K,  Na,  Cl,  and  hematocrit.
Furosemide  group  (n  =  49)  Azosemide  group  (n  =  48)
Baseline  After  3  months  Baseline  After  3  months
SBP  (mmHg) 136.1  ±  26.2  133.2  ±  23.6  135.3  ±  27.9  133.4  ±  23.6
DBP (mmHg)  71.9  ±  14.4  71.7  ±  12.3  71.5  ±  12.0  73.9  ±  10.0
PRA (ng/ml/h)  4.3  ±  5.4  4.1  ±  5.3  4.5  ±  6.1  4.7  ±  6.2
NE (pg/ml) 513.0 ±  280.3  519.3 ±  361.8  472.2  ±  267.6  479.6  ±  432.1
BUN (mg/dl) 23.0 ±  8.2  22.5 ±  8.5  21.1 ±  9.0  21.6  ±  9.3
Cr (mg/dl) 0.97 ±  0.42  1.02 ±  0.42* 1.03 ±  0.33  1.09 ±  0.35**
K  (mmol) 4.3 ±  0.5  4.4 ±  0.5  4.4 ±  0.5  4.3 ±  0.5
Na (mmol)  142.0  ±  3.5  141.4  ±  2.9  142.8  ±  3.3  142.2  ±  2.4
Cl (mmol)  106.6  ±  12.6  102.8  ±  14.1  104.4  ±  3.7  105.0  ±  3.0
Ht (%)  37.2  ±  5.7  36.9  ±  5.0  36.1  ±  5.4  35.9  ±  4.9
SBP, systolic blood pressure; DBP, diastolic blood pressure; PRA, plasma renin activity; NE, norepinephrine; BUN, blood urea nitrogen;
Cr, creatine; Ht, hematocrit.
* p < 0.05 vs baseline in furosemide group.
** p < 0.01 vs baseline in azosemide group.
Figure  3  Changes  in  brain  natriuretic  peptide  (BNP)  (A)  and
atrial  natriuretic  peptide  (ANP)  (B)  after  3  months.  White  bars
are furosemide  group;  black  bars  are  azosemide  group.
Figure  4  Changes  in  left  ventricular  (LV)  Tei  index  (A)  and
right ventricular  (RV)  Tei  index  (B)  after  3  months.  White  bars
are furosemide  group;  black  bars  are  azosemide  group.  *p  <  0.05
for comparison  between  baseline  and  after  3  months.
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ie  compared  the  effect  on  neurohumoral  factors  between
urosemide  and  azosemide,  and  found  that  long-acting
zosemide  signiﬁcantly  decreased  plasma  BNP  and  ANP  lev-
ls  compared  with  short-acting  furosemide.
ANP  and  BNP  are  secreted  mainly  from  the  atria  and
entricles,  respectively,  and  these  markers  are  predictors
f  LV  dysfunction.  The  plasma  ANP  and  BNP  levels  are
onsidered  a  particularly  useful  predictive  biomarker  for
rognosis  and  cardiovascular  events  in  patients  with  CHF
18—20]  and  acute  myocardial  infarction  [21]. In  the  SAVE
tudy,  where  neurohumoral  factors  were  measured  12  days
fter  myocardial  infarction  in  534  patients,  multivariate
nalysis  revealed  that  only  plasma  ANP  level  and  plasma
enin  activity  on  day  12  after  disease  onset  were  associated
ith  outcome  in  patients  with  acute  myocardial  infarction
22].  In  the  Val-HeFT  study,  plasma  levels  of  norepineph-
ine,  aldosterone,  and  BNP  were  measured  in  4300  patients
ith  moderate  to  severe  heart  failure,  and  the  plasma  BNP
evel  showed  the  greatest  prognostic  value  [23]. In  the
resent  study,  these  parameters  signiﬁcantly  decreased  in
he  azosemide  group  compared  to  those  in  the  furosemide
roup,  suggesting  that  long-acting  diuretics  may  be  useful
or  improving  cardiac  function  and  prognosis  in  CHF.
McCurley  et  al.  conducted  a  placebo-controlled  com-
arative  study  to  investigate  the  effect  of  furosemide  on
rogression  of  LV  dysfunction  in  a  heart  failure  model,
nd  reported  that  furosemide  signiﬁcantly  accelerated  the
rogression  of  LV  systolic  dysfunction  [24]. In  addition,
tarklint  et  al.  reported  that  administration  of  furosemide
id  not  induce  any  signiﬁcant  change  in  plasma  ANP
nd  BNP  levels  in  CHF  patients  [25]. The  present  study
lso  demonstrated  that  neurohumoral  factors  and  car-
iac  function  assessed  by  echocardiography  were  not  fully
mproved  by  furosemide.  Several  investigators  reported
hat  the  furosemide  causes  excessive  volume  loss  and
lectrolyte  disturbances  due  to  its  strong  and  rapid  diuretic
ffect,  and  the  response  to  the  rapid  volume  reduction
ay  lead  to  activation  of  the  sympathetic  nervous  system
nd  the  renin—angiotensin—aldosterone  system,  resulting
n  increased  plasma  ANP  and  BNP  levels  [26,27], although
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we  failed  to  show  the  differences  in  responses  of  sym-
pathetic  nerve  activity  and  electrolytes  between  the  two
groups.  It  is  likely  that  these  undesirable  effects  of  rapid
diuretics  might  disturb  the  improvement  in  cardiac  function
expected  with  furosemide.  In  contrast,  azosemide  showed
signiﬁcantly  decreased  plasma  BNP  and  ANP  levels  compared
to  furosemide  in  the  present  study.  This  result  suggests
that  the  beneﬁt  of  azosemide  is  associated  with  its  mild
and  long-acting  diuretic  effect  without  inducing  unfavorable
responses,  resulting  in  high  usefulness  for  treatment  of  CHF.
Limitations
We  did  not  evaluate  the  effect  of  diuretics  on  the  prognosis
of  heart  failure.  Further  clinical  examinations  are  needed
to  examine  the  different  outcomes  in  CHF  patients  treated
with  long-  and  short-acting  diuretics.  Comparison  of  the
effect  of  furosemide  and  azosemide  on  the  prognosis  in
CHF  patients  is  currently  underway  in  a  prospective  mul-
ticenter  study  [28]. The  relatively  low  prescription  rate  of
-blockers,  and  the  high  cardiac  valvular  disease  preva-
lence,  which  is  estimated  to  be  50%,  might  make  our  study
difﬁcult  to  apply  to  general  heart  failure.
Conclusion
Long-acting  azosemide,  with  coadministration  of  an  ACE
inhibitor,  is  suggested  to  be  more  useful  than  short-acting
furosemide  in  improving  neurohumoral  factors  in  patients
with  CHF.
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